Drug Farm Secures $55 Million Series D, Accelerating AI-Powered Drug Development
July 20, 2026, 3:37 pm
Drug Farm closed a $55M Series D, fueling its AI-driven drug pipeline. The NYC-Shanghai biotech will advance clinical programs for DF-003, targeting ROSAH syndrome and cardiovascular disease, and DF-006 for hepatitis B. Its proprietary platforms merge genetics and AI to uncover novel targets. This capital accelerates global development, strengthens regulatory efforts, and expands R&D in rare, metabolic, and infectious diseases. A significant leap for AI in drug discovery, positioning Drug Farm for pivotal trials and market expansion.
Drug Farm, a pioneering biotechnology company, has finalized the initial close of its Series D financing round. The company secured $55 million. This substantial investment propels Drug Farm's advanced clinical and preclinical development pipeline. The financing round garnered robust support. New and existing investors participated. This underscores strong market confidence in Drug Farm's innovative approach.
The funding round saw co-leadership from prominent entities. Shanghai Pudong Leading Area Investment Center and Shanghai Puxing Collaborative Private Equity Fund Partnership Enterprise spearheaded the investment. New investors also joined. These included Tukar Capital, Fuzhou Xinhe Fund, Shenzhen Luohu Donghai Chempartner Investment Fund, and Keyuan Pharma. Existing supporters reaffirmed their commitment. BioVeda China Fund (BVCF), YD Capital, Jiashan State VC, Detong Capital, Wedo Capital, and Biometas continued their participation. This diverse investor base highlights broad support for Drug Farm's strategic vision.
Drug Farm plans to deploy these funds strategically. The capital will advance its clinical and preclinical pipeline programs. Global clinical development efforts will accelerate. Regulatory activities across critical markets will strengthen. The company also aims to expand its research and development capabilities significantly. These steps are crucial for bringing novel therapies to patients worldwide.
Founded by Dr. Tian Xu, Drug Farm operates from both New York City and Shanghai, China. The company focuses on developing groundbreaking treatments. Its pipeline addresses ROSAH syndrome, various heart and kidney diseases, hepatitis B, and metabolic disorders. Dr. Henri Lichenstein serves as CEO. Dr. Tony Xu is the COO. This leadership team guides the company's ambitious goals.
Central to Drug Farm's innovation are its proprietary technology platforms. These platforms integrate genetics and artificial intelligence (AI). They identify and validate novel drug targets directly within living biological systems. This unique approach, epitomized by its IDInVivo+ platform, enhances the efficiency and precision of drug discovery. The MedChem5 platform complements this, advancing multiple first-in-class drug candidates into clinical development rapidly.
A key asset in Drug Farm's pipeline is DF-003. This proprietary, first-in-class drug emerged from the MedChem5 platform. It inhibits ALPK1 and its disease-causing variants. DF-003 targets multiple conditions. These include ROSAH syndrome, atherosclerotic cardiovascular disease, and other heart and kidney ailments. The drug is currently in a Phase 1b study for ROSAH syndrome. Early clinical data shows promise. It demonstrates improvement across various symptoms of the rare disease.
DF-003 represents a significant milestone for AI in drug development. It is among the first AI-developed drugs projected to enter a Phase 3 trial. The new financing will fund a pivotal trial for ROSAH syndrome. It will also support achieving clinical proof of concept in atherosclerotic cardiovascular disease. Regulatory bodies recognize DF-003's potential. The FDA granted it Fast Track, Orphan Drug, Rare Pediatric Disease, and Rare Disease Evidence Principles designations. These designations highlight its importance for unmet medical needs.
Another crucial pipeline candidate is DF-006. This drug is a proprietary, first-in-class, orally administered ALPK1 agonist immunomodulator. Its mechanism stimulates local innate immunity in the liver. DF-006 has completed single and multiple ascending dose evaluations in healthy volunteers. It also underwent multiple ascending dose evaluation in virologically suppressed HBeAg negative chronic hepatitis B patients. Encouraging anti-HBV activity was observed in these studies.
Drug Farm is actively expanding collaborations for DF-006. The company entered a clinical partnership with Xiamen Amoytop Biotech. This collaboration focuses on developing DF-006 for treating hepatitis B and hepatocellular carcinoma. This strategic alliance broadens the drug's potential impact and market reach.
The Series D financing positions Drug Farm for continued global leadership. The company will push its AI-enabled drug candidates through advanced development stages. It also plans to broaden its research into diverse therapeutic areas. These include metabolic, autoimmune, infectious disease, cardiovascular, kidney, and other rare disease indications. This multi-faceted approach aims to address a wide spectrum of critical health challenges.
Drug Farm's commitment to innovation remains steadfast. Its integrated use of genetics and AI defines a new paradigm in biotech. This strategy allows for rapid identification and validation of novel drug targets. It streamlines the entire drug discovery process. The current funding round validates this powerful scientific and business model. Investors see the tangible value in Drug Farm's platform. They recognize its potential to generate breakthrough therapies.
The biotechnology sector continues its rapid evolution. Drug Farm stands at the forefront. It leverages cutting-edge technology to solve complex medical problems. The $55 million investment is more than capital. It is an endorsement of a vision. It supports a future where AI-driven science delivers life-changing medicines to patients faster. The company moves closer to pivotal trials. It prepares for market entry. Its impact on global health could be profound. This funding marks a pivotal moment for the company's trajectory.
Drug Farm, a pioneering biotechnology company, has finalized the initial close of its Series D financing round. The company secured $55 million. This substantial investment propels Drug Farm's advanced clinical and preclinical development pipeline. The financing round garnered robust support. New and existing investors participated. This underscores strong market confidence in Drug Farm's innovative approach.
The funding round saw co-leadership from prominent entities. Shanghai Pudong Leading Area Investment Center and Shanghai Puxing Collaborative Private Equity Fund Partnership Enterprise spearheaded the investment. New investors also joined. These included Tukar Capital, Fuzhou Xinhe Fund, Shenzhen Luohu Donghai Chempartner Investment Fund, and Keyuan Pharma. Existing supporters reaffirmed their commitment. BioVeda China Fund (BVCF), YD Capital, Jiashan State VC, Detong Capital, Wedo Capital, and Biometas continued their participation. This diverse investor base highlights broad support for Drug Farm's strategic vision.
Drug Farm plans to deploy these funds strategically. The capital will advance its clinical and preclinical pipeline programs. Global clinical development efforts will accelerate. Regulatory activities across critical markets will strengthen. The company also aims to expand its research and development capabilities significantly. These steps are crucial for bringing novel therapies to patients worldwide.
Founded by Dr. Tian Xu, Drug Farm operates from both New York City and Shanghai, China. The company focuses on developing groundbreaking treatments. Its pipeline addresses ROSAH syndrome, various heart and kidney diseases, hepatitis B, and metabolic disorders. Dr. Henri Lichenstein serves as CEO. Dr. Tony Xu is the COO. This leadership team guides the company's ambitious goals.
Central to Drug Farm's innovation are its proprietary technology platforms. These platforms integrate genetics and artificial intelligence (AI). They identify and validate novel drug targets directly within living biological systems. This unique approach, epitomized by its IDInVivo+ platform, enhances the efficiency and precision of drug discovery. The MedChem5 platform complements this, advancing multiple first-in-class drug candidates into clinical development rapidly.
A key asset in Drug Farm's pipeline is DF-003. This proprietary, first-in-class drug emerged from the MedChem5 platform. It inhibits ALPK1 and its disease-causing variants. DF-003 targets multiple conditions. These include ROSAH syndrome, atherosclerotic cardiovascular disease, and other heart and kidney ailments. The drug is currently in a Phase 1b study for ROSAH syndrome. Early clinical data shows promise. It demonstrates improvement across various symptoms of the rare disease.
DF-003 represents a significant milestone for AI in drug development. It is among the first AI-developed drugs projected to enter a Phase 3 trial. The new financing will fund a pivotal trial for ROSAH syndrome. It will also support achieving clinical proof of concept in atherosclerotic cardiovascular disease. Regulatory bodies recognize DF-003's potential. The FDA granted it Fast Track, Orphan Drug, Rare Pediatric Disease, and Rare Disease Evidence Principles designations. These designations highlight its importance for unmet medical needs.
Another crucial pipeline candidate is DF-006. This drug is a proprietary, first-in-class, orally administered ALPK1 agonist immunomodulator. Its mechanism stimulates local innate immunity in the liver. DF-006 has completed single and multiple ascending dose evaluations in healthy volunteers. It also underwent multiple ascending dose evaluation in virologically suppressed HBeAg negative chronic hepatitis B patients. Encouraging anti-HBV activity was observed in these studies.
Drug Farm is actively expanding collaborations for DF-006. The company entered a clinical partnership with Xiamen Amoytop Biotech. This collaboration focuses on developing DF-006 for treating hepatitis B and hepatocellular carcinoma. This strategic alliance broadens the drug's potential impact and market reach.
The Series D financing positions Drug Farm for continued global leadership. The company will push its AI-enabled drug candidates through advanced development stages. It also plans to broaden its research into diverse therapeutic areas. These include metabolic, autoimmune, infectious disease, cardiovascular, kidney, and other rare disease indications. This multi-faceted approach aims to address a wide spectrum of critical health challenges.
Drug Farm's commitment to innovation remains steadfast. Its integrated use of genetics and AI defines a new paradigm in biotech. This strategy allows for rapid identification and validation of novel drug targets. It streamlines the entire drug discovery process. The current funding round validates this powerful scientific and business model. Investors see the tangible value in Drug Farm's platform. They recognize its potential to generate breakthrough therapies.
The biotechnology sector continues its rapid evolution. Drug Farm stands at the forefront. It leverages cutting-edge technology to solve complex medical problems. The $55 million investment is more than capital. It is an endorsement of a vision. It supports a future where AI-driven science delivers life-changing medicines to patients faster. The company moves closer to pivotal trials. It prepares for market entry. Its impact on global health could be profound. This funding marks a pivotal moment for the company's trajectory.